Apyx Medical Corporation specializes in innovative surgical aesthetic devices based on proprietary Helium Plasma Platform Technology, including the Renuvion and AYON systems. The company’s revenue showed modest growth in recent years but remains unprofitable with persistent operating losses and negative cash flow. Its strategic progress includes FDA clearance for AYON and geographic expansion via a joint venture in China. However, macroeconomic headwinds, regulatory complexity, supply chain risks, and competitive dynamics continue to challenge near-term profitability and cash flow sustainability.